Publishing of Orion Corporation's Interim Report for January-September 2015 on 27 October 2015
(Thomson Reuters ONE) -
ORION CORPORATION STOCK EXCHANGE RELEASE 13 OCTOBER 2015 at 2:30 P.M. EEST
Publishing of Orion Corporation's Interim Report for January-September 2015 on
27 October 2015
Orion will publish its Interim Report for January-September 2015 on Tuesday, 27
October 2015 approximately at 12:00 noon Finnish time (EET). The release and
related presentation material in Finnish and in English will be available on the
Group's homepage at www.orion.fi/en/investors promptly after the publishing.
News conference for analysts and media
A news conference for analysts and media will be held on Tuesday 27 October
2015 at 13:30 EET at Hotel Kämp, address Pohjoisesplanadi 29, Helsinki.
President and CEO Timo Lappalainen will give a brief presentation in English on
the financial review. Questions can be asked after the result presentation.
Participants should be prepared to present a photo ID on request.
Live webcast and conference call
A link to the live webcast will be available at Orion's website
www.orion.fi/en/investors.
The conference call ID is 955325 and the phone numbers to participate the
conference are:
Finland: +358 (0)9 2313 9202
Sweden: +46 (0)8 5052 0114
UK: +44 (0)207 1620 177
USA: +1 334 323 6203
News conference recordings
A recording of the event in English and a recording of the presentation by the
President and CEO in Finnish will be available on the Orion website later the
same day.
Silent period
The silent period preceding the publication is ongoing and continues until the
disclosure.
Orion Corporation
Timo Lappalainen Jari Karlson
President and CEO CFO
Contact person:
Tuukka Hirvonen, Communications Manager, IR & Financial Communications
tel. +358 10 426 2721
Publisher:
Orion Corporation
www.orion.fi/en
Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical ingredients
and diagnostic tests. The company is continuously developing new drugs and
treatment methods. The core therapy areas of Orion's pharmaceutical R&D are
central nervous system (CNS) disorders, oncology and respiratory for which Orion
developes inhaled Easyhaler® pulmonary drugs.
Orion's net sales in 2014 amounted to EUR 1,015 million and the company had
about 3,500 employees. Orion's A and B shares are listed on NASDAQ Helsinki.
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Orion Oyj via GlobeNewswire
[HUG#1958499]
Unternehmensinformation / Kurzprofil:
Datum: 13.10.2015 - 13:31 Uhr
Sprache: Deutsch
News-ID 426516
Anzahl Zeichen: 3426
contact information:
Town:
Espoo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 156 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Publishing of Orion Corporation's Interim Report for January-September 2015 on 27 October 2015"
steht unter der journalistisch-redaktionellen Verantwortung von
Orion Oyj (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
